Abstract: The present invention concerns a polymeric material for the production of a non-viral nanoparticle. The polymeric material comprises (i) a hydrophilic linear polymer having a first end and a second end, (iii) a cross-linkable cationic polymer covalently bonded to the first end of the hydrophilic linear polymer, and (iii) at least one targeting/penetrating peptide covalently associated to the second end of the hydrophilic linear polymer. Also disclosed herein are nanoparticles produced with these polymeric material, processes for making the polymeric material and the nanoparticles as well as use of the nanoparticles.

Abstract: Synthetic antimicrobial peptides, compositions comprising thereof, and methods of use for modulating one or more symptoms of an infection in a subject are disclosed. In some aspects, the infection is caused by mycobacteria, for example, a nontuberculous mycobacterium such as Mycobacterium abscessus. In other aspects, the infection is caused by Escherichia coli, Pseudomonas aeruginosa, or methicillin-resistant Staphylococcus aureus (MRSA). Also disclosed are methods of identifying synthetic antimicrobial peptides against a pathogen with no known effective treatment using a library of synthetic peptides.

Abstract: The present subject matter provides compounds, compositions, and methods for identifying, monitoring, treating, and removing diseased tissue. Compounds, compositions, and methods for identifying, monitoring, and detecting circulating fluids such as blood are also provided.

Abstract: A teicoplanin derivative useful for treating an infectious disease, having the structure of formula (I): or the pharmaceutically acceptable salt, solvate, stereoisomer, derivative or prodrug thereof. In an exemplary compound of formula (I), R1 is R2 is H, R3 is —N(CH3)2, and R4 is H.

Abstract: Novel crystalline particles, methods for manufacture of crystalline particles, and solid unit dosage forms, particularly tablets or capsules, of bis-choline tetrathiomolybdate are provided. In particular, provided herein are crystalline particles that allow for a more stable solid unit dosage form of bis-choline tetrathiomolybdate.

Abstract: The present invention relates to methods of treating or preventing AIBD.

Abstract: A nanoscale drug carrier capable of crossing the blood-brain barrier. Said carrier can target brain lesions (brain tumors or other neurodegenerative diseases). The targeting drug carrier capable of crossing the blood-brain barrier comprises all-heavy-chain human ferritin or a functional fragments reconstituted structure or a mutant thereof. The manner for crossing the blood-brain barrier of the drug carrier is receptor-mediated transcytosis. The drug carrier provides an effective nanoscale drug carrier for the treatment of brain tumors or other neurodegenerative diseases.

Abstract: Described herein are oral delivery systems for use in delivering live mammalian cells to the intestinal tract of an individual.

Abstract: The invention pertains to the use of soluble sodium in the manufacture of a composition or kit of parts for (therapeutically) improving and prolonging blood plasma uridine levels and tissue availability of uridine, and/or for treating or preventing impaired blood plasma uridine levels and tissue availability of uridine, and/or for preventing/treating disorders associated with impaired blood plasma and tissue availability of uridine, in a mammal, preferably a human being, by orally co-administering soluble sodium and uridine in a molar ratio of soluble sodium to uridine of more than 1:1, preferably more than 1.5:1, more preferably more than 2:1, even more preferably at least 2.5:1, even more preferably at least 2.8:1, more preferably 3:1-15:1, most preferably 3:1-10:1, particularly 3:1-5:1.

Abstract: The disclosure provides, inter alia, compositions including cell-nanoparticle constructs and drug loaded nanoparticles, and methods for their use in the treatment of cancer. Also provided are unmodified cisplatin molecules encapsulated by silica nanoparticles, and their use in the treatment of cancer.

Abstract: Compounds of Formula (I)a or (I)b: including certain quinone derivatives, and the corresponding pharmaceutical compositions, which may serve to modulate ferroptosis in a subject. Also disclosed herein are the preparations of these compounds and pharmaceutical compositions and their potential uses in the manufacture of a medicament in reducing reactive oxygen species (ROS) in a cell and for preventing, treating, ameliorating certain related disorder or a disease.

Abstract: Provided herein are peptides comprising an amino acid sequence having at least about 85% sequence identity to RYRPRAPIIAVT (SEQ ID NO: 1). These cationic peptides inhibit PKM2 methylation and may be used in the treatment of breast cancer and other diseases or conditions in which PKM2 is overexpressed. Such PKM2 peptides may be delivered to cancer cells using pH sensitive unimolecular nanoparticles comprising anionic polymers.

Abstract: Disclosed are recombinant bacteriophage constructs and related exogenous peptide sequences for generating immune responses against CD47. The disclosed recombinant phage constructs bind to antibodies against CD47 and can be administered to an animal to generate an immune response against CD47, including generating anti-CD47 antibodies. The disclosed recombinant phage may comprise an amino acid sequence of CD47, epitopic fragments, variants, or functional mimics thereof. Also disclosed are methods for making and selecting such recombinant phage constructs and compositions that comprise such constructs (e.g., compositions for inducing an immune response against CD47 including pharmaceutical or veterinary compositions used as vaccines). Also disclosed are recombinant polynucleotides comprising genomic nucleic acid of the recombinant phage constructs disclosed herein.

Abstract: The present invention relates to a method for preparing biodegradable microspheres using a single-phase mixed solution containing water, alcohol, and dichloromethane. Provided is a method for preparing a biodegradable microsphere having a uniform drug loading efficiency by preparing and using a single-phase mixed solution in which no phase separation occurs without using a thickener and a surfactant. The preparation method of the present invention has the feature of keeping the content of a loaded drug uniform until a final biodegradable microsphere is prepared, by using a single-phase mixed solution in which no phase separation by a solvent occurs in the preparation process. Thus, the preparation method of the present invention is remarkably useful for the preparation of biodegradable microspheres.

Abstract: Described is a crosslinked hydrogel for muscle stem cell culture and a preparation method and use thereof. The preparation method includes: dissolving collagen to prepare a solution and adding alginate and heparan sulfate proteoglycan and uniformly mixing with the collagen solution; adding ?-PL and TGase into the solution, uniformly stirring, and putting a slurry into a mold for crosslinking to obtain the hydrogel. The hydrogel is prepared by linking the collagen, the polylysine, and the heparan sulfate proteoglycan using the TGase to form covalent crosslinking, and forming a compact three-dimensional “egg box” network structure through a physical electrostatic interaction between the polylysine and the alginate.

Abstract: Compositions containing quaternary compounds in which the nitrogen atom is substituted by at least one alkyl group having at least 12 carbon atoms, and the composition includes at least 20% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 14 carbon atoms and more than 5%, preferably more than 7% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 16 carbon atoms. Also, ophthalmic oil-in-water emulsions containing such compositions, the ophthalmic emulsions being useful for eye care or for the treatment of eye conditions.

Abstract: The present invention relates to novel peptides and a pharmaceutical compositions comprising the same. The peptide compounds and compositions disclosed herein are useful as therapeutic agents for treating eye diseases. When administered to the eyes, the peptide compounds and compositions disclosed herein increase the amount of tear secretion and promotes recovery of a damaged cornea.

Abstract: Disclosed herein are synthetic hydrogels suitable for delivering antimicrobial proteins, optionally in combination with bone regenerating agents to injured tissues. The hydrogels can include lysostaphin and one or more bone morphogenic proteins. The hydrogels are composed of a network of crosslinked hydrophilic polymers and adhesion peptides.

Abstract: Embodiments of the present invention relate to a novel compound of Formula (I) or stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, for use in treatment of infection caused by Gram-negative bacteria.

Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.